目的：探讨彩色多普勒超声在心脏手术中的应用价值。方法：在14例心脏病手术中，于心脏修复完成后经心外膜超声检查。结果：一例先天性心脏病室间隔缺损修补片周少量残余漏；一例风湿性心脏病二尖瓣、主动脉瓣置换术后，主动脉瓣下少量返流；因不构成血流动力学的改变，未行二次修复。结论：可即时、准确地为外科医生提供相关信息，评价手术效果。
目的 提高对囊性纤维化的认识。 方法 2011年11月收治1例自幼有临床表现的囊性纤维化患者，回顾其诊断及治疗经过，复习相关文献总结其临床特征、诊疗进展及预后评价。 结果 囊性纤维化起病年龄较早，患者自幼年起即反复出现肺、消化道、肝脏等多系统病变，最终导致多器官功能衰竭。 结论 应提高对囊性纤维化的识别度，对于发病年龄过早、反复发作的严重支气管扩张，伴随生长发育延迟、肝硬化等临床征象应注意对囊性纤维化的筛查。
Ambulatory surgery has been vigorously promoted in China while there is a lack of unified management norms. Shanghai has a long-term pilot operation of ambulatory surgery in China, which has a certain management foundation. And it has actively promoted the standardized management since 2014. This article introduces the development and preparation of the Shanghai local standard The Hospital Management Specification of Ambulatory Surgery and the main structure and key technical content of the standard, in order to promote the standardization of ambulatory surgery management for reference.
Objective To understand the status of needs, demands and utilization of health services of urban and rural residents in Chongqing, so as to provide references for the evaluation of health services status and policy making and regulating. Methods The data from family health questionnaire of health service survey in Western China in 2008 were descriptively analyzed. Results The two-week prevalence rate was 216.9‰ and the two-week hospital visit rate was 211.5‰. The sick people who did not seek medical care accounted for 56.2% among the sick population. The chronic disease prevalence rate was 226.4‰. The annual hospitalization rate was 77.1‰. Conclusion During the past five-year from 2003 to 2008, the needs of health services in Chongqing have had no big change, but the chronic disease prevalence rate has been in uptrend, and the utilization has obviously increased. And the economic factor is still the major cause for impeding residents to seek medical care. So it’s necessary to strengthen the construction of primary health care institutions, to improve the level of health insurance system, and to decrease the disparity in urban and rural areas.
目的 检测分化抑制因子1（Id-1）在肝细胞肝癌组织中和正常肝组织中的表达情况，了解Id-1与肝细胞肝癌患者预后关系。 方法 对获得的19例肝细胞肝癌组织标本和8例正常肝组织进行免疫组织化学染色，并对染色结果进行分级。借助SPSS软件，分析肝细胞肝癌组织标本与正常肝组织标本中的Id-1表达强度区别，Id-1与甲胎蛋白（AFP）相关性，及Id-1表达强度与肝癌患者预后之间的关系。 结果 免疫组织化学染色结果显示所有标本均表达为阳性，其中3例（+），7例（++），10例（+++）7例（++++），肝细胞肝癌组织标本与正常肝组织标本差异有统计学意义（P＜0.05）；Id-1表达与血液中AFP水平相关不显著（r=−0.121，P=0.621）；Spearman等级相关分析显示患者生存时间与Id-1表达呈负相关（r=−0.567，P=0.011）。 结论 Id-1在肝癌组织中表达增高 ，Id-1表达水平与生存时间呈负相关，但和AFP无明显相关。
【摘要】 目的 探讨胰腺癌早期诊断的要点及误诊因素。 方法 回顾性分析2009年7月8日收治的1例以腹胀、呕吐为主要表现的胰腺癌患者。 结果 患者经及时剖腹探查确诊为胰腺癌并行手术切除。 结论 胰腺癌起病隐匿，其早期误诊率高，进行胰腺癌的早期诊断、避免误诊是提高预后的重点和难点。【Abstract】 Objective To explore the main points of early diagnosis of pancreatic cancer and its misdiagnosis factors. Methods The clinical data of one patient with pancreatic cancer on the 8th July, 2009 was retrospectively analyzed. The chief complaints included abdominal distension and vomiting. Results By exploratory surgery in time,the patient was diagnosed as pancreatic cancer and underwent the resection. Conclusion The onset of pancreatic cancer is very insidious,usually with a high misdiagnosis rate. How to make the right early diagnosis and to avoid misdiagnosis are the focal points of improving the prognosis.
ObjectiveTo systematically evaluate the association between human leukocyte antigen DQ (HLA-DQ) gene rs2856718A>G, rs9275572A>G polymorphisms and the risk of chronic hepatitis B. MethodsPubMed, EMbase, CBM, WanFang Data, CNKI and VIP databases were systematically searched from inception to April 2015 to collect case-control studies about HLA-DQ gene polymorphisms and the risk of chronic hepatitis B. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed using RevMan 5.3 software, and Stata 12.0 software was used for sensitivity and publication bias analysis. ResultsA total of 6 papers involving 8 case-control studies were included, which involved 3 690 cases and 6 267 controls. The results of meta-analysis showed that:the rs2856718A>G polymorphism was associated with the decreased risk of chronic hepatitis B (AG+GG vs. AA:OR=0.63, 95%CI 0.51 to 0.78, P=0.000; GG vs. AG+AA:OR=0.69, 95%CI 0.61 to 0.79, P=0.000; GG vs. AA:OR=0.56, 95%CI 0.48 to 0.64, P=0.000; GA vs. AA:OR=0.64, 95%CI 0.47 to 0.88, P=0.006; G vs. A:OR=0.74, 95%CI 0.68 to 0.79, P=0.000). The rs9275572A>G polymorphism was not associated with the risk of chronic hepatitis B (AG+GG vs. AA:OR=1.11, 95%CI 0.55 to 2.23, P=0.770; GG vs. AG+AA:OR=1.10, 95%CI 0.84 to 1.45, P=0.500; GG vs. AA:OR=1.14, 95%CI 0.54 to 2.41, P=0.730; AG vs. AA:OR=1.06, 95%CI 0.56 to 2.02, P=0.860; G vs. A:OR=1.11, 95%CI 0.83 to 1.48, P=0.490). ConclusionHLA-DQ gene rs2856718 A>G polymorphism is significantly associated with decreased risk of chronic hepatitis B, but the rs9271319 A>G polymorphism is not associated with the risk of chronic hepatitis B.
ObjectiveTo systematically review clinical value of des-γ-carboxy prothrombin (DCP) in the diagnostic of primary hepatocellular carcinoma (PHC).MethodsDatabases including PubMed, The Cochrane Library, EMbase, Medline (Ovid), CNKI, VIP, WanFang Data and CBM were electronically searched to collect relevant studies on DCP in the diagnosis of PHC from inception to December 31st, 2018. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed by using Meta-Disc 1.4 software and RevMan 5.3 software.ResultsA total of 50 studies involving 15 099 cases were included. The results of meta-analysis showed that the pooled sensitivity, pooled specificity, pooled positive likelihood ratio, pooled negative likelihood ratio, pooled diagnostic odds ratio and area under the curve of SROC were 0.69 (95%CI 0.67 to 0.70), 0.89 (95%CI 0.89 to 0.90), 7.35 (95%CI 6.08 to 8.90), 0.31 (95%CI 0.27 to 0.35), 26.63 (95%CI 20.42 to 34.73) and 0.909 9, respectively.ConclusionsSerum DCP has higher diagnostic efficacy for PHC, especially with higher specificity of diagnosis. Due to the limited quality and quantity of included studies, the above results should be validated by more studies.
Objective To analyze the prognosis and indications of transjugular intrahepatic portosystemic shunt (TIPS) in patients with Budd-Chiari syndrome (BCS). MethodsPatients with primary BCS who received TIPS in the Department of Gastroenterology, West China Hospital of Sichuan University between February 2009 and February 2020 were retrospectively reviewed. The medical history, preoperative imaging, surgical records, and postoperative outpatient follow-up medical records were recorded. The laboratory indexes before and after operation were compared, and the cumulative free from hepatic encephalopathy rate, stent patency rate, and cumulative survive rate were calculated. Cox proportional hazards model was used to analyze the independent risk factors of hepatic encephalopathy, shunt dysfunction and death. Results A total of 48 patients were included. The main indications for TIPS included variceal bleeding (16 cases), refractory ascites (24 cases), and diffuse obstruction of hepatic vein with acute liver function impairment (8 cases). The cumulative 1 year, 2 years and 3 years of free from hepatic encephalopathy rates were 92.3%, 89.2% and 85.3%, respectively. The stent patency rates were 89.7%, 72.2% and 54.8% at postoperative 1 year, 3 years and 5 years, respectively. The cumulative survival rates were 86.0%, 79.5% and 71.4% at postoperative 1 year, 3 years and 5 years, respectively. Conclusion TIPS can achieve good efficacy in patients with BCS, and most patients receive TIPS for portal hypertension complications rather than acute liver function impairment.